Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: Metabolic profile in diet-induced obese models and aspects of central activity

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 384, Issue 6, 2011, Pages 565-581

  Jacobson, Laura H ^c   Commerford, S Renee ^a   Gerber, Sarah P ^a   Chen, Yu Alice ^b   Dardik, Beatriz ^a   Chaperon, Frederique ^c   Schwartzkopf, Chad ^a   Nguyen Tran, Van ^b   Hollenbeck, Thomas ^b   McNamara, Peter ^b   He, Xiaohui ^b   Liu, Hong ^b   Seidel, H Martin ^b   Jaton, Anne Liese ^c   Gromada, Jesper ^a   Teixeira, Sandra ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Body weight; Cannabinoid receptor 1; Obesity; Plasma lipids; REM sleep

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO PHENYL) 1 PHENYL 6 (4 PYRAZIN 2 YL PHENYL) 1,5 DIHYDRO PYRAZOLO[3,4 D]PYRIMIDIN 4 ONE; CANNABINOID 1 RECEPTOR AGONIST; DESIPRAMINE; DICLOFENAC; PROPAFENONE; PYRIMIDINE; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONDITIONING; CONTROLLED STUDY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG STRUCTURE; HAPLORHINI; HYPOTHERMIA; IN VITRO STUDY; IN VIVO STUDY; LEARNING DISORDER; LOCOMOTION; MALE; METABOLIC PARAMETERS; NONHUMAN; OBESITY; RAT; REM SLEEP; WEIGHT REDUCTION;

ANIMALS; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INVERSE AGONISM; EXTINCTION, PSYCHOLOGICAL; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; OBESITY; PIPERIDINES; PYRAZOLES; PYRIMIDINONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; SLEEP, REM; TISSUE DISTRIBUTION;

EID: 83555173393     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-011-0686-y     Document Type: Article

References (47)

1. LJ Aronne S Tonstad M Moreno I Gantz N Erondu S Suryawanshi C Molony S Sieberts J Nayee AG Meehan D Shapiro SB Heymsfield KD Kaufman JM Amatruda 2010 A clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study Int J Obes (Lond) 34 5 919 935 10.1038/ijo.2010.21 1:CAS:528:DC%2BC3cXlslylur4%3D
2. MJ Banker TH Clark JA Williams 2003 Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding J Pharm Sci 92 967 974 12712416 10.1002/jps.10332 1:CAS:528:DC%2BD3sXjs1ehsrs%3D (Pubitemid 36523442)
3. L Bellocchio P Lafenêtre A Cannich D Cota N Puente P Grandes F Chaouloff PV Piazza G Marsicano 2010 Bimodal control of stimulated food intake by the endocannabinoid system Nat Neurosci 13 3 281 283 20139974 10.1038/nn.2494 1:CAS:528:DC%2BC3cXhs1Olsr8%3D
4. A Cannich CT Wotjak K Kamprath H Hermann B Lutz G Marsicano 2004 CB1 cannabinoid receptors modulate kinase and phosphatase activity during extinction of conditioned fear in mice Learn Mem 11 625 632 15466318 10.1101/lm.77904 (Pubitemid 39299714)
5. F Chaperon MH Thiébot 1999 Behavioral effects of cannabinoid agents in animals Crit Rev Neurobiol 13 243 281 10803637 1:CAS:528: DC%2BD3cXjt1Cqtbc%3D (Pubitemid 30265251)
6. Y Cheng WH Prusoff 1973 Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Biochem Pharmacol 22 3099 3108 4202581 10.1016/0006-2952(73)90196-2 1:CAS:528:DyaE2cXhtVGgs7c%3D
7. D Cota G Marsicano M Tschöp Y Grübler C Flachskamm M Schubert D Auer A Yassouridis C Thöne-Reineke S Ortmann F Tomassoni C Cervino E Nisoli AC Linthorst R Pasquali B Lutz GK Stalla U Pagotto 2003 The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis J Clin Invest 112 3 423 431 12897210 1:CAS:528: DC%2BD3sXmtFemtrg%3D (Pubitemid 38063771)
8. D Cota MH Tschöp TL Horvath AS Levine 2005 Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res Rev 51 1 85 107 16364446 10.1016/j.brainresrev.2005.10.004 (Pubitemid 43782532)
9. M Davis K Ressler BO Rothbaum R Richardson 2006 Effects of d-cycloserine on extinction: translation from preclinical to clinical work Biol Psychiatry 60 337 343 10.1016/j.biopsych.2006.03.084 (Pubitemid 44215855)
10. WA Devane L Hanus A Breuer RG Pertwee LA Stevenson G Griffin D Gibson A Mandelbaum A Etinger R Mechoulam 1992 Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 1946 1949 1470919 10.1126/science.1470919 1:CAS:528:DyaK3sXpvVKntg%3D%3D (Pubitemid 23026736)
11. J Ellis JD Pediani M Canals S Milasta G Milligan 2006 Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function J Biol Chem 2281 50 38812 38824 10.1074/jbc.M602494200 (Pubitemid 46042008)
12. European Medicines Agency (2009) Acomplia Product Summary: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000666/WC500021287.pdf
13. RW Foltin M Haney 2007 Effects of the cannabinoid antagonist SR141716 (rimonabant) and d-amphetamine on palatable food and food pellet intake in non-human primates Pharmacol Biochem Behav 86 766 773 17445873 10.1016/j.pbb.2007.03.004 1:CAS:528:DC%2BD2sXmtVGhtr0%3D (Pubitemid 46839130)
14. J Fu P Li X Ouyang C Gu Z Song J Gao L Han S Feng S Tian B Hu 2007 Rapid eye movement sleep deprivation selectively impairs recall of fear extinction in hippocampus-independent tasks in rats Neuroscience 144 1186 1192 17157993 10.1016/j.neuroscience.2006.10.050 1:CAS:528:DC%2BD2sXhtVartrg%3D (Pubitemid 46123805)
15. M Gary-Bobo G Elachouri JF Gallas P Janiak P Marini C Ravinet-Trillou M Chabbert N Cruccioli C Pfersdorff C Rogue M Arnone T Croci P Soubrie F Oury-Donat JP Maffrand B Scatton F Lacheretz G Le Fur JM Herbert M Bensaid 2007 Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats Hepatology 46 122 129 17526015 10.1002/hep.21641 1:CAS:528:DC%2BD2sXosVylt7s%3D (Pubitemid 47171928)
16. S Haj-Dahmane RY Shen 2005 The wake-promoting peptide orexin-B inhibits glutamatergic transmission to dorsal raphe nucleus serotonin neurons through retrograde endocannabinoid signaling J Neurosci 25 4 896 905 15673670 10.1523/JNEUROSCI.3258-04.2005 1:CAS:528:DC%2BD2MXhtlaltrc%3D (Pubitemid 40171005)
17. AC Howlett 1995 Pharmacology of cannabinoid receptors Annu Rev Pharmacol Toxicol 35 607 634 7598509 10.1146/annurev.pa.35.040195.003135 1:CAS:528:DyaK2MXlt1Gqsr4%3D
18. H Huang C Acuna-Goycolea Y Li HM Cheng K Obrietan AN van den Pol 2007 Cannabinoids excite hypothalamic melanin-concentrating hormone but inhibit hypocretin/orexin neurons: implications for cannabinoid actions on food intake and cognitive arousal J Neurosci 27 18 4870 4881 17475795 10.1523/JNEUROSCI. 0732-07.2007 1:CAS:528:DC%2BD2sXlsV2rtr0%3D (Pubitemid 46699061)
19. BD Hudson TE Hébert ME Kelly 2010 Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor Mol Pharmacol 77 1 1 9 19837905 10.1124/mol.109.060251 1:CAS:528:DC%2BC3cXovFymtA%3D%3D
20. W Jacob A Yassouridis G Marsicano K Monory B Lutz CT Wotjak 2009 Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission Genes Brain Behav 8 7 685 698 19563475 10.1111/j.1601-183X.2009.00512.x 1:CAS:528:DC%2BD1MXhtlyqurzL
21. DR Janero A Makriyannis 2009 Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis Expert Opin Emerging Drugs 14 43 65 10.1517/14728210902736568 1:CAS:528:DC%2BD1MXivFSmtbc%3D
22. P Janiak B Poirier J-P Bidouard C Cadrouvele F Pierre L Gouraud I Barbosa J Dedio J-P Maffrand G Le Fur S O'Connor J-M Herbert 2007 Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats Kidney Int 72 1345 2357 17882151 10.1038/sj.ki.5002540 1:CAS:528:DC%2BD2sXhtlWjtrrI (Pubitemid 350126778)
23. G Kunos 2007 Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system? Am J Med 120 S18 S24 17720356 10.1016/j.amjmed.2007.06.007 1:CAS:528:DC%2BD2sXhtlGgs7nL (Pubitemid 47284984)
24. LS Lin TJ Lanza Jr JP Jewell P Liu SK Shah H Qi X Tong J Wang SS Xu TM Fong CP Shen J Lao JC Xiao LP Shearman DS Stribling K Rosko A Strack DJ Marsh Y Feng S Kumar K Samuel W Yin LH Van der Ploeg MT Goulet WK Hagmann 2006 Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity J Med Chem 49 26 7584 7587 17181138 10.1021/jm060996+ 1:CAS:528:DC%2BD28XhtlCqsLvK (Pubitemid 46033647)
25. G Marsicano CT Wotjak SC Azad T Bisogno G Rammes MG Cascio H Hermann J Tang C Hofmann W Zieglgänsberger V Di Marzo B Lutz 2002 The endogenous cannabinoid system controls extinction of aversive memories Nature 418 530 534 12152079 10.1038/nature00839 1:CAS:528:DC%2BD38Xls12nur4%3D (Pubitemid 34851398)
26. B Martin D Compton B Thomas W Prescott P Little R Razdan M Johnson L Melvin R Mechoulam S Ward 1991 Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs Pharmacol Biochem Behav 40 471 478 1666911 10.1016/0091-3057(91)90349-7 1:CAS:528:DyaK38XnsFOjsA%3D%3D
27. I Matias V Di Marzo 2007 Endocannabinoids and the control of energy balance Trends Endocrinol Metab 18 1 27 37 17141520 10.1016/j.tem.2006.11.006 1:CAS:528:DC%2BD2sXhsFelsg%3D%3D (Pubitemid 44960014)
28. LA Matsuda SJ Lolait MJ Brownstein AC Young TI Bonner 1990 Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 346 561 564 2165569 10.1038/346561a0 1:CAS:528:DyaK3cXls1Ghu7w%3D (Pubitemid 20238806)
29. FA Moreira B Lutz 2008 The endocannabinoid system: emotion, learning and addiction Addict Biol 13 2 196 212 18422832 10.1111/j.1369-1600.2008.00104.x 1:CAS:528:DC%2BD1cXnvV2jt7Y%3D (Pubitemid 351698889)
30. S Munro KL Thomas M Abu-Shaar 1993 Molecular characterization of a peripheral receptor for cannabinoids Nature 365 61 65 7689702 10.1038/365061a0 1:CAS:528:DyaK3sXmsVWiurk%3D (Pubitemid 23305569)
31. L Navarro M Martínez-vargas E Murillo-rodríguez A Landa M Méndez-díaz O Prospéro-garcía 2003 Potential role of the cannabinoid receptor CB1 in rapid eye movement sleep rebound Neuroscience 120 855 859 12895525 10.1016/S0306-4522(03)00339-7 1:CAS:528: DC%2BD3sXlvVClurg%3D (Pubitemid 36928082)
32. F Niyuhire SA Varvel AJ Thorpe RJ Stokes JL Wiley AH Lichtman 2007 The disruptive effects of the CB1 receptor antagonist rimonabant on extinction learning in mice are task-specific Psychopharmacol 191 223 231 10.1007/s00213-006-0650-6 1:CAS:528:DC%2BD2sXitlCksL0%3D (Pubitemid 46354610)
33. FJ Pavón A Serrano V Pérez-Valero N Jagerovic L Hernández-Folgado FJ Bermúdez-Silva M Macías P Goya FR de Fonseca 2008 Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats J Neuroendocrinol Suppl 1 116 123 10.1111/j.1365-2826.2008.01693.x (Pubitemid 351552685)
34. FX Pi-Sunyer LJ Aronne HM Heshmati J Devin J Rosenstock RIO-North America Study Group 2006 Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial JAMA 295 761 775 16478899 10.1001/jama.295.7.761 1:CAS:528:DC%2BD28XhsFOrs7g%3D (Pubitemid 43244304)
35. J Proietto A Rissanen JB Harp N Erondu Q Yu S Suryawanshi ME Jones AO Johnson-Levonas SB Heymsfield KD Kaufman JM Amatruda 2010 A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study Int J Obes (Lond) 34 8 1243 1254 10.1038/ijo.2010.38 1:CAS:528:DC%2BC3cXhtVSmsLvF
36. C Ravinet Trillou M Arnone C Delgorge N Gonalons P Keane JP Maffrand P Soubrie 2003 Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice Am J Physiol Reg Integr Comp Physiol 284 R345 R353 (Pubitemid 36120150)
37. A Rechtschaffen BM Bergmann MA Gilliland K Bauer 1999 Effects of method, duration, and sleep stage on rebounds from sleep deprivation in the rat Sleep 22 11 31 9989363 1:STN:280:DyaK1M7ktl2mtw%3D%3D (Pubitemid 29097896)
38. RJ Rodgers I Haller J Halasz E Mikics 2003 'One trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141 716A in the mouse elevated plus-maze Eur J Neurosci 17 1279 1286 12670316 10.1046/j.1460-9568.2003.02548.x 1:STN:280:DC%2BD3s7lsVCrug%3D%3D (Pubitemid 36459782)
39. T Sakurai 2007 The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness Nat Rev Neurosci 8 3 171 181 17299454 10.1038/nrn2092 1:CAS:528:DC%2BD2sXhvVyqu7s%3D (Pubitemid 46294664)
40. V Santucci JJ Storme P Soubrié G Le Fur 1996 Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis Life Sci 58 103 110 10.1016/0024-3205(95)02319-4
41. AJ Silvestri 2005 REM sleep deprivation affects extinction of cued but not contextual fear conditioning Physiol Behav 84 343 349 15763570 10.1016/j.physbeh.2004.11.011 1:CAS:528:DC%2BD2MXitFCju78%3D (Pubitemid 40342587)
42. J Simiand M Keane PE Keane P Soubrié 1998 SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset Behav Pharmacol 9 179 181 10065938 1:CAS:528:DyaK1cXivVWktbk%3D (Pubitemid 28186515)
43. J Tam VK Vemuri J Liu S Bátkai B Mukhopadhyay G Godlewski D Osei-Hyiaman S Ohnuma SV Ambudkar J Pickel A Makriyannis G Kunos 2010 Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity J Clin Invest 120 8 2953 2966 20664173 10.1172/JCI42551 1:CAS:528:DC%2BC3cXhtVaiurzM
44. BF Thomas 2009 Neuroanatomical basis for therapeutic applications of cannabinoid receptor 1 antagonists Drug Devel Res 70 527 554 10.1002/ddr.20333 1:CAS:528:DC%2BD1MXhsFGrtrvE
45. 1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study Eur Heart J 29 1761 1771 18417461 10.1093/eurheartj/ehn076 (Pubitemid 352019811)
46. TA Wadden K Fujioka S Toubro I Gantz N E Erondu M Chen S Suryawanshi W Carofano AO Johnson-Levonas D R Shapiro KD Kaufman SB Heymsfield JM Amatruda 2010 A randomized trial of lifestyle modification and taranabant for maintaining weight loss achieved with a low-calorie diet Obesity (Silver Spring) 18 12 2301 2310 10.1038/oby.2010.67
47. T Westlake A Howlett T Bonner L Matsuda M Herkenham 1994 Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains Neuroscience 63 637 652 7898667 10.1016/0306-4522(94)90511-8 1:CAS:528:DyaK2MXisFeqtbk%3D (Pubitemid 24360219)